High-flow nasal cannula oxygen therapy versus noninvasive ventilation in immunocompromised patients with acute respiratory failure: an observational cohort study by unknown
Coudroy et al. Ann. Intensive Care  (2016) 6:45 
DOI 10.1186/s13613-016-0151-7
RESEARCH
High-flow nasal cannula oxygen 
therapy versus noninvasive ventilation 
in immunocompromised patients  
with acute respiratory failure: an observational 
cohort study
Rémi Coudroy1,2*, Angéline Jamet1, Philippe Petua1, René Robert1,2, Jean‑Pierre Frat1,2 and Arnaud W. Thille1,2
Abstract 
Background: Acute respiratory failure is the main cause of admission to intensive care unit in immunocompromised 
patients. In this subset of patients, the beneficial effects of noninvasive ventilation (NIV) as compared to standard oxy‑
gen remain debated. High‑flow nasal cannula oxygen therapy (HFNC) is an alternative to standard oxygen or NIV, and 
its use in hypoxemic patients has been growing. Therefore, we aimed to compare outcomes of immunocompromised 
patients treated using HFNC alone or NIV as a first‑line therapy for acute respiratory failure in an observational cohort 
study over an 8‑year period. Patients with acute‑on‑chronic respiratory failure, those treated with standard oxygen 
alone or needing immediate intubation, and those with a do‑not‑intubate order were excluded.
Results: Among the 115 patients analyzed, 60 (52 %) were treated with HFNC alone and 55 (48 %) with NIV as first‑
line therapy with 30 patients (55 %) receiving HFNC and 25 patients (45 %) standard oxygen between NIV sessions. 
The rates of intubation and 28‑day mortality were higher in patients treated with NIV than with HFNC (55 vs. 35 %, 
p = 0.04, and 40 vs. 20 %, p = 0.02 log‑rank test, respectively). Using propensity score‑matched analysis, NIV was asso‑
ciated with mortality. Using multivariate analysis, NIV was independently associated with intubation and mortality.
Conclusions: Based on this observational cohort study including immunocompromised patients admitted to inten‑
sive care unit for acute respiratory failure, intubation and mortality rates could be lower in patients treated with HFNC 
alone than with NIV. The use of NIV remained independently associated with poor outcomes.
Keywords: Acute respiratory failure, Immunosuppression, Noninvasive positive pressure ventilation, Acute lung 
injury, Mechanical ventilation, High‑flow oxygen therapy
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Background
Acute respiratory failure is the main cause of admission 
to intensive care unit (ICU) in immunocompromised 
patients [1]. In this subset of patients, the need for intu-
bation and invasive mechanical ventilation is associ-
ated with particularly high mortality rates, reaching 
70 % of cases [2–4]. In the early 2000s, two randomized 
controlled trials reported lower rates of intubation and 
mortality with the use of noninvasive ventilation (NIV) 
as compared to standard oxygen [5, 6]. However, given 
the small samples of patients included in these stud-
ies, experts suggested that NIV could be used in immu-
nocompromised patients with acute respiratory failure, 
but the strength of recommendation was assessed as 
weak [7]. As a consequence, so far NIV has been used 
as a first-line therapy in only 25–40  % of immunocom-
promised patients admitted to ICU for acute respiratory 
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failure [1, 8–10]. Recently, a large randomized controlled 
trial did not confirm the potential benefits of NIV and 
in fact found similar outcomes in immunocompromised 
patients with acute respiratory failure treated with NIV 
or oxygen alone [11]. It is important to note that, in this 
study, oxygen therapy could be delivered using either 
standard oxygen or high-flow oxygen through nasal can-
nula (HFNC).
HFNC is a recent technique that delivers heated and 
humidified oxygen at high-flow rates [12]. Several physi-
ological studies have shown HFNC to be better toler-
ated than standard oxygen delivered through a mask 
[13–15]. High-flow rates of fresh gas help to increase 
the fraction of inspired oxygen (FiO2) [16], to generate 
low levels of positive end-expiratory pressure [17], and 
to decrease physiological dead space by flushing expired 
carbon dioxide in the upper airways [18]. The result is 
a decrease in work of breathing [19] and dyspnea [14] 
while the heating and humidification of inspired gases 
may prevent thick secretions and atelectasis. HFNC 
could not only offer an alternative to standard oxygen 
in hypoxemic patients, but also avoid the need for NIV. 
In a recent multicenter randomized controlled trial, the 
mortality rate in patients with acute respiratory failure 
treated with HFNC alone was significantly lower in both 
those treated with standard oxygen and in those treated 
with NIV [20]. In this study, patients treated with NIV 
also received HFNC between NIV sessions, thereby sug-
gesting a direct deleterious effect of NIV compared to 
the group receiving HFNC alone. That said, as patients 
with neutropenia were excluded from the trial, these 
results could not be extrapolated to all immunocompro-
mised patients.
Given the fact that use of HFNC in patients with acute 
respiratory failure has been increasing in our unit over 
recent years, we aimed to compare the outcomes of 
immunocompromised patients treated with HFNC alone 
or with NIV as first-line therapy.
Some of the results of this study were reported in the 
form of an abstract at the 2016 meeting of the French 
Intensive Care Society in Paris, France.
Methods
Study design
Between 1 January 2007 and 31 December 2014, dis-
charge reports from all patients admitted to our 15-bed 
medical ICU in a tertiary hospital were retrospectively 
reviewed. This study was approved by the Ethics Com-
mittee of the French Intensive Care Society (Société de 
Réanimation de Langue Française, SRLF, CE no. 14-27), 
and given its observational nature, informed consent was 
waived.
Screening of patients
We screened all patients admitted for acute respiratory 
failure defined by the following criteria: a respiratory rate 
≥25 breaths/min or clinical signs of respiratory distress, 
and a calculated PaO2-to-FiO2 ratio ≤300  mmHg, FiO2 
being estimated as follows: (oxygen flow in liters per min-
ute × 0.03) + 0.21 [20]. Among them, we included those 
who had immunosuppression caused by hematologic or 
solid cancer, stem cell or solid organ transplantation, a 
steroid dose of more than 0.5 mg/kg for at least 1 month, 
or cytotoxic drugs for non-malignant disease or acquired 
immune deficiency syndrome. Patients with acute-on-
chronic respiratory failure, those treated with standard 
oxygen alone or needing immediate intubation, and those 
with a do-not-intubate order were excluded from the 
analysis.
Classification of patients
Patients were classified according to the time from the 
onset of acute respiratory failure and the start of the 
first-line strategy of ventilatory support including NIV 
or HFNC. All patients in whom NIV was started within 
the first 6  h after the onset of acute respiratory failure 
were included in the NIV group if they received at least 
2 h of NIV within the first 24 h. Those who were treated 
with HFNC within the first 6  h after the onset of acute 
respiratory failure were included in the HFNC group, 
even if they received late NIV as a rescue therapy beyond 
the first 6  h. Therefore, patients initially treated with 
HFNC and who received late NIV as rescue therapy, 
i.e., the most severe patients, remained classified in the 
HFNC group. We excluded patients treated with stand-
ard oxygen during the first 6  h and who received short 
NIV (<2 h) considered as preoxygenation in case of frank 
respiratory worsening leading to intubation, and those 
treated with standard oxygen during the first 6 h and who 
received late NIV as rescue therapy. Each patient was 
classified by consensus of three senior intensivists (RC, 
JPF, and AWT) blinded to outcomes up to full agreement.
In our unit, the criteria to decide intubation were 
the same as those used in our previous studies [15, 20]: 
uncontrolled shock defined by mean arterial pressure 
≤65  mm Hg despite a 30  ml/kg crystalloid fluid chal-
lenge and increasing doses of vasopressors, neurological 
impairment defined by a Glasgow score ≤12, or signs 
of persisting or worsening respiratory failure as defined 
by at least two of the following criteria: respiratory rate 
>40 breaths per minute, lack of improvement in signs of 
high respiratory muscle workload, development of copi-
ous tracheal secretions, acidosis with pH <7.35, an SpO2 
<90  % for more than 5  min without technical dysfunc-
tion, or a poor response to oxygenation techniques.
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Data collection
 For all included patients, we collected age, gender, func-
tional status before ICU admission using the Knaus 
chronic health status score [21], Mac Cabe score reflect-
ing the severity of underlying disease [22], severity scores 
including the Simplified Acute Physiology Score II [23], 
and the modified Sequential Organ Failure Assessment 
(excluding respiratory item) [24], type of immunosup-
pression, and year of ICU admission. Clinical, radiologi-
cal, and biological parameters at inclusion such as heart 
rate, systolic blood pressure, respiratory rate, SpO2, body 
temperature, bilateral lung infiltrates on chest X-ray, 
arterial pH, sodium bicarbonate, and PaO2-to-FiO2 ratio 
were recorded. Two senior physicians reviewed all charts 
to assess the reason for acute respiratory failure (AJ and 
PP). Initial settings during NIV or HFNC and ventilation 
characteristics during the ICU stay were collected.
Outcomes
Primary end-point was the mortality rate at day 28. Sec-
ondary outcomes included intubation rate, length of 
mechanical ventilation and ICU stay, in-ICU mortality, 
and variables associated with intubation and mortality at 
day 28.
Statistical analysis
Continuous variables were expressed as mean ± stand-
ard deviation (SD) or as median [interquartile range, 
from 25th to 75th percentiles] according to their distri-
bution using the Kolmogorov–Smirnov test and com-
pared using the Mann–Whitney or the Student’s t test 
as appropriate. Dichotomous variables were expressed 
in percentage and compared using the Fischer’s exact 
test or the Chi-square test as appropriate. We per-
formed two multivariate analyses using a backward 
step-down logistic regression model including early 
clinical and biological variables associated first with 
mortality at day 28 and second with intubation, with a 
p value <0.15 using univariate analysis. As the year of 
ICU admission was different between the 2 groups, this 
variable was forced in the logistical regression model. 
Kaplan–Meier curves were plotted to assess time from 
the onset of acute respiratory failure to mortality within 
the first 28  days in the 2 groups and compared by the 
log-rank test. Given the baseline differences between 
groups, a propensity score was computed by using logis-
tic regression with the dependent variables associated 
with mortality at day 28 (age and use of vasopressors 
within 24 h after ICU admission) to estimate the effect 
of NIV on mortality at day 28 [25]. A matching algo-
rithm was performed according to the propensity score. 
Adjusted outcomes between patients who were or were 
not treated with NIV were compared using the paired t 
test or the Wilcoxon matched paired test as appropri-
ate to compare adjusted outcomes. We considered two-
tailed p values <0.05 as significant. Statistical analyses 
were performed using the statistical software package 
XLstat® (Addinsoft, Paris, France), GraphPadPrism 5® 
(La Jolla, CA, USA) and R statistical package (online at 
http://www.R-project.org).
Results
Of the 5244 patients admitted to our unit over an 8-year 
period, 1299 (25 %) were admitted for acute respiratory 
failure. Among them, 267 (21 %) were immunocompro-
mised (Fig. 1). Baseline characteristics of the 115 patients 
(43  %) included in the analysis are given in Table  1. In 
the NIV group, patients were more likely to be male, to 
have hypercapnia and alkalemia at admission, whereas 
in the HFNC group they tended to be older. In the first 
half of the study period, patients were more likely to be 
treated with NIV as first-line therapy than in the second 
half: 68 % (26 of 38 patients) received NIV from 2007 ver-
sus 2010 versus 38 % (22 of the 77 patients) from 2011 to 
2014, p =  0.003. Intubation rates in the NIV group did 
not differ between the 2 periods: 57  % (15/26 patients) 
in the first period versus 52 % (15/29) in the second one 
(p = 0.66). 
In the NIV group, initial FiO2 was 0.6 [0.5–0.9], 
whereas levels of pressure support and positive end-
expiratory pressure were 10  cm H2O [8–12] and 4  cm 
H2O [4–5], respectively. Mean expiratory tidal vol-
ume delivered during the first 24  h after NIV initiation 
was 9.0 ± 2.4 ml/kg of predicted body weight. NIV was 
applied during 2.0 days [1.0–4.0] in median for a duration 
of 8 h [4–11] during the first 24 h. Among the 55 patients 
treated with NIV, 25 patients (45  %) received stand-
ard oxygen between NIV sessions, whereas the 30 other 
patients (55 %) received HFNC.
In the HFNC group, FiO2 was 0.6 [0.5–1], whereas gas 
flow was 50  l/min [40–50]. HFNC was applied continu-
ously for a total duration of 2.0 days [1.0–4.0] in median. 
Eight patients in the HFNC group (13 %) received NIV as 
rescue therapy during their ICU stay.
Overall intubation rate was 44  % (51 of 115 patients), 
and overall mortality at day 28 was 30  % (34 of 115 
patients). The rates of intubation and of mortality in ICU 
and at day 28 were significantly lower in the HFNC group 
than in the NIV group (Table 1 and Fig. 2). Mortality of 
patients who needed intubation tended to be significantly 
lower in the HFNC group (9/21 patients, 43  %) than in 
the NIV group (21/30 patients, 70 %, p = 0.05).
In the NIV group, outcomes did not significantly dif-
fer between the patients who received HFNC between 
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NIV sessions and those who received standard oxygen: 
the rates of intubation were 47  % (14/30) versus 64  % 
(16/25), respectively, p =  0.28; the rates of mortality at 
day 28 were 36  % (11/30) versus 44  % (11/25), respec-
tively, p = 0.59.
Variables associated with intubation and mortality at 
day 28 in the overall population are given in Additional 
file 1 and Table 2, respectively. Using multivariate analy-
sis, the 3 variables independently associated with intuba-
tion were severity at admission in the ICU as indicated 
by a high SAPS II, need for vasopressor within the 24 h 
after ICU admission, and use of NIV (Table  3). Use of 
NIV remained associated with mortality at day 28 inde-
pendently from age and the need for vasopressor within 
24 h after ICU admission (Table 3), even after forcing the 
year of admission in the model. 
Baseline characteristics and outcomes of the 57 patients 
included in the propensity score-matched cohort are dis-
played in Table  4. In-ICU mortality at day 28 remained 
significantly lower in the HFNC than in the NIV group 
after matching on age and need for vasopressors within 
24  h after ICU admission (Table  4). Using multivariate 
analysis in the matched cohort, NIV as a first-line therapy 
was the only factor independently associated with mor-
tality at day 28 with and adjusted odds ratio of 4.03 and a 
95 % confidence interval of [1.09–14.93], even after forc-
ing the year of ICU admission.
Discussion
Our main finding is that immunocompromised patients 
admitted to ICU for acute respiratory failure had higher 
mortality when treated with NIV than those treated with 
HFNC alone. Moreover, they were more likely to be intu-
bated and to have prolonged ICU length of stay. After 
adjustment, NIV remained independently associated 
with intubation and mortality at day 28.
In our study, intubation and mortality rates in the NIV 
group of the overall cohort were 55 and 40  %, respec-
tively. These results are in keeping with the intubation 
and mortality rates reported in recent cohort studies [2, 
1299 paents admied for acute respiratory failure
267 immunocompromised paents admied for acute respiratory failure 
142 paents excluded:
• 38 with chronic obstrucve lung disease
• 66 treated with standard oxygen alone
• 20 with do not intubate order
• 16 requiring immediate intubaon
• 2 missing data
125 immunocompromised paents admied for acute respiratory failure 
and requiring a first-line treatment with NIV and/or HFNC
55 paents treated with 
noninvasive venlaon
60 paents treated with high-flow 
oxygen therapy through nasal cannula
10 paents treated with standard oxygen
excluded because of late NIV (n=8) or NIV
used as preoxygenaon (n=2)
Fig. 1 Flow chart of included patients over an 8‑year period
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Table 1 Comparison of baseline characteristics and outcomes between patients treated by noninvasive positive pressure 
ventilation (NIV) or high-flow nasal cannula (HFNC) oxygen therapy alone
NIV (n = 55) HFNC (n = 60) p value
Age (years) 58 (44–66) 62 (50–70) 0.06
Gender (male) 42 (76 %) 35 (58 %) 0.048
Knaus chronic health status score 0.46
 A 15 (27 %) 19 (32 %)
 B 17 (31 %) 22 (37 %)
 C 21 (38 %) 15 (25 %)
 D 2 (3.6 %) 4 (6.7 %)
Mac Cabe classification 0.20
 1 20 (36 %) 19 (32 %)
 2 19 (35 %) 30 (50 %)
 3 16 (29 %) 11 (18 %)
SAPS II at ICU admission (points) 42 ± 11 46 ± 13 0.10
Modified SOFA score at inclusion (points) 3 (1–6) 4 (1–6) 0.28
 Type of immunosuppression 0.30
  Hematologic cancer or neutropenia 33 (60 %) 31 (52 %)
  Solid cancer 11 (20 %) 8 (13 %)
  Drug‑induced immunosuppression 10 (18 %) 20 (33 %)
  Acquired immune deficiency syndrome 1 (2 %) 1 (2 %)
 Cause of respiratory failure 0.38
  Documented infection 24 (44 %) 31 (52 %)
  Cardiogenic pulmonary edema 5 (9 %) 5 (8 %)
  Specific 13 (24 %) 6 (10 %)
  Other identified causes 7 (13 %) 11 (18 %)
  Not identified cause 6 (11 %) 7 (12 %)
 Clinical and biological parameters at inclusion
  Heart rate (beats/min) 111 ± 22 113 ± 23 0.71
  Systolic blood pressure (mmHg) 130 (113–150) 119 (110–147) 0.28
  Respiratory rate (breaths/min) 30 (26–33) 29 (26–32) 0.75
  SpO2 (%) 94 (91–98) 96 (94–99) 0.02
  Body temperature (°C) 37.8 ± 1.1 38.0 ± 1.1 0.47
  Bilateral lung infiltrates on chest X‑ray 46 (84 %) 50 (83 %) >0.99
  Arterial pH 7.44 (7.40–7.47) 7.46 (7.43–7.50) 0.02
  PaO2‑to‑FiO2 ratio (mmHg) 141 (111–177) 149 (107–204) 0.19
  PaO2‑to‑FiO2 ratio ≤ 200 mmHg 47 (85 %) 44 (73 %) 0.17
  PaCO2 (mmHg) 37 (32–45) 32 (29–38) <0.0001
  PaCO2 > 45 mmHg 12 (22 %) 2 (3 %) 0.003
  Sodium bicarbonate (mmol/l) 25 (22–28) 21 (24–26) 0.04
Vasopressors within 24 h after ICU admission 9 (16 %) 14 (23 %) 0.35
Time from admission to ventilatory support initiation (h) 1 (0–1) 1 (0–1) 0.62
Need for immunosuppressive drug during ICU stay 13 (24 %) 15 (25 %) >0.99
Admission before 2011 26 (47 %) 12 (20 %) <0.0001
 Primary outcome
  28‑day mortality 22 (40 %) 12 (20 %) 0.02
 Secondary outcomes
  Intubation 30 (55 %) 21 (35 %) 0.04
  Time from admission to intubation (h) 28 (18–49) 35 (9–49) 0.99
  Length of invasive mechanical ventilation (days) 8 (4–11) 7 (4–12) 0.63
  Length of ICU stay (days) 8 (5–13) 7 (4–9) 0.08
  In‑ICU mortality 20 (36 %) 9 (15 %) 0.01
Nominal variables are given as number (%), and continuous data are given as median (25th–75th percentile) or mean ± standard deviation (SD) according to their 
distribution using the Kolmogorov–Smirnov test
SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment
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26–28], reinforcing the external validation of our results. 
Conversely, the rates of intubation and mortality in our 
patients treated with HFNC alone were 35 and 20  %, 
respectively, which are markedly lower than the rates 
reported in the above-mentioned studies [2, 26–28]. 
Therefore, these differences seem more likely due to a 
decrease in intubation or mortality rates observed in the 
HFNC group rather than an excess of intubation or mor-
tality in the NIV group.
In contrast to patients with chronic obstructive pul-
monary disease [29, 30] or cardiogenic pulmonary 
edema [31], the benefits of NIV remain unclear in 
immunocompromised patients with acute respiratory 
failure. To date, three randomized controlled trials 
have compared the use of NIV versus standard oxygen 
in immunocompromised patients with acute respira-
tory failure [5, 6, 11]. In a first trial including 40 patients 
with solid organ transplantation, the rate of intubation 
was significantly reduced in patients treated with NIV 
[5]. However, nearly one quarter of the patients had car-
diogenic pulmonary edema [5], a condition for which 
the benefits of NIV are supported by a strong level of 
evidence [31]. In a second trial including 52 patients, 
the rates of intubation and mortality were significantly 
lower in patients treated with NIV [6]. However, these 
beneficial effects were observed only in patients with 
hematologic cancer or neutropenia, which accounted 
only for 15 patients per group [6]. In the most recent 
trial including 374 patients, intubation and mortality 
rates did not differ between the two groups [11]. How-
ever, respiratory rate and oxygen requirement at inclu-
sion were lower than in our study and in the two 
previous trials [5, 6], perhaps illustrating a lower sever-
ity of respiratory failure, which may have attenuated the 
impact of NIV on outcomes.
The case volume of patients treated with first-line 
NIV may also have influence on outcomes, with lower 
expected intubation rates in highly skilled centers. These 
findings have already been suggested in patients treated 
with NIV for cardiogenic pulmonary edema or acute-on-
chronic respiratory failure [9, 32–35]. In our high case-
volume center, this would have favoured the NIV group 
and attenuated the outcome difference between the 2 
groups, which was not the case.
A recent retrospective study including 178 immu-
nocompromised patients with acute respiratory fail-
ure suggested that the best strategy consisted in use of 
NIV associated with HFNC between NIV sessions [28]. 
The 37 % mortality rate recorded in the group treated 
by NIV and HFNC was almost the same as that of our 
patients treated by NIV (40  %). Once again, this mor-
tality rate remained markedly higher than the 20 % rate 
we report herein in our patients treated with HFNC 
alone. Therefore, use of HFNC alone without NIV 
could be the treatment of choice in immunocompro-
mised patients admitted to ICU for acute respiratory 
failure.
Although use of HFNC alone has been poorly evalu-
ated in immunocompromised patients with acute res-
piratory failure, our results are in line with those found 
recently in a large multicenter randomized controlled 
trial [20]. Indeed, this study showed a significantly 
reduced mortality rate in patients treated with HFNC 
alone as compared to those treated by NIV with HFNC 
between NIV sessions [20]. In this trial, about one-third 
of included patients were immunocompromised, and the 
rates of intubation and in-ICU mortality in the HFNC 
group were 38 and 11  %, respectively, which are in line 
with those we report.
The beneficial effects of HFNC could be largely due 
to tolerance. HFNC seems better tolerated than NIV 
in patients with acute respiratory failure with a higher 
degree of comfort, a reduction in the severity of dyspnea 
and a decreased respiratory rate [15, 20]. Although these 
criteria were not assessed in our study, we believe that 
our findings may be extrapolated to immunocompro-
mised patients. By contrast, NIV could be harmful due 
to potential ventilator-induced lung injury generated by 
pressure support that increases tidal volumes [36] and 
leads to high transpulmonary pressure [37]. Indeed, it 







P value = 0,0221 by log-rank test
HFNC group
NIV group




Fig. 2 Figure showing the Kaplan–Meier plots of the cumulative 
survival rates within the 28 days following the onset of acute respira‑
tory failure in ICU in the overall population. The rate of mortality was 
significantly lower in patients treated with high‑flow nasal cannula 
(HFNC) oxygen therapy alone (blue line) than in patients treated with 
noninvasive ventilation (NIV) as first‑line therapy (green line), decreas‑
ing from 40 % (22/55) to 20 % (12/60) p = 0.0221 by log‑rank test
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Table 2 Univariate analysis of variables associated with mortality at day 28 in the overall population
Nominal variables are given as number (%), and continuous data are given as median (25th–75th percentile) or mean ± standard deviation (SD) according to their 
distribution using the Kolmogorov–Smirnov test
SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment
Survivors (n = 81) Non-survivors (n = 34) Odds ratio (95 % CI) p value
Demographic variables
 Age (years) 56 ± 15 60 ± 15 1.02 (0.99–1.05) 0.13
 Gender (male) 54 (67 %) 23 (68 %) 0.96 (0.41–2.25) 0.92
 ICU admission before 2011 24 (30 %) 14 (41 %) 1.66 (0.72–3.82) 0.23
 Noninvasive ventilation as a first‑line therapy 34 (42 %) 22 (65 %) 2.67 (1.16–6.12) 0.03
 SAPS II score 42 ± 12 47 ± 13 1.036 (1.00–1.07) 0.04
 Modified SOFA score excluding respiratory item 3 (1–6) 4 (1–7) 1.06 (0.93–1.21) 0.44
 Knaus chronic health status score 0.32
  A 24 (30 %) 10 (29 %) 1
  B 31 (38 %) 8 (24 %) 0.62 (0.21–1.81)
  C 23 (28 %) 13 (38 %) 1.36 (0.50–3.70)
  D 3 (3.7 %) 3 (8.8 %) 2.40 (0.41–13.98)
 Mac Cabe classification 0.32
  1 28 (35 %) 11 (32 %) 1
  2 37 (46 %) 12 (35 %) 0.83 (0.32–2.14)
  3 16 (20 %) 11 (32 %) 1.75 (0.62–4.94)
 Type of immunosuppression 0.08
  Hematologic cancer or neutropenia 49 (60 %) 15 (44 %) 1
  Solid cancer 9 (11 %) 10 (29 %) 3.53 (1.21–10.27)
 Drug‑induced immunosuppression 21 (26 %) 9 (26 %) 1.41 (0.54–3.70)
  Acquired immune deficiency syndrome 2 (2 %) 0 (0 %) 0.64 (0.02–27.52)
Variables at inclusion
 Heart rate (bpm) 111 ± 23 113 ± 21 1.00 (0.99–1.02) 0.71
 Systolic arterial blood pressure (mmHg) 126 ± 24 126 ± 29 1.00 (0.98–1.02) 0.96
 Diastolic arterial blood pressure (mmHg) 67 ± 18 67 ± 13 1.00 (0.98–1.02) 0.99
 Respiratory rate (breaths/min) 28 (25–32) 30 (27–34) 1.04 (0.98–1.10) 0.19
 SpO2 (%) 96 (94–99) 94 (90–97) 0.90 (0.83–0.97) 0.01
 Body temperature (°C) 38.0 ± 1.2 37.7 ± 0.9 0.82 (0.58–1.18) 0.29
 pH 7.46 (7.42–7.49) 7.44 (7.40–7.49) 0.59 (0.00–21.07) 0.30
 Sodium bicarbonate (mmol/l) 24 (22–27) 24 (22–27) 1.03 (0.94–1.12) 0.83
 PaO2‑to‑FiO2 ratio (mmHg) 158 ± 59 141 ± 48 0.99 (0.99–1.00) 0.15
 PaO2‑to‑FiO2 ratio ≤ 200 mmHg 62 (77 %) 29 (85 %) 1.78 (0.60–5.23) 0.29
 PaO2 (mmHg) 74 (61–88) 70 (57–93) 1.00 (0.99–1.01) 0.38
 PaCO2 (mmHg) 34 (31–40) 34 (31–45) 1.01 (0.97–1.06) 0.56
 PaCO2 > 45 mmHg 8 (10 %) 6 (18 %) 1.96 (0.62–6.14) 0.24
 Bilateral lung infiltrate 69 (85 %) 27 (79 %) 0.67 (0.24–1.89) 0.45
Vasopressors within 24 h after ICU admission 10 (12 %) 13 (38 %) 2.18 (0.85–5.62) 0.11
Immunosuppressive drug during ICU stay 22 (27 %) 6 (17 %) 0.58 (0.21–1.58) 0.35
Cause of respiratory failure 0.13
 Documented infection 38 (47 %) 17 (50 %) 1
 Cardiogenic pulmonary edema 10 (12 %) 0 (0 %) 0.11 (0.01–2.17)
 Specific 11 (14 %) 8 (24 %) 1.63 (0.56–4.76)
 Other identified causes 12 (15 %) 6 (18 %) 1.14 (0.37–3.54)
 Not identified cause 10 (12 %) 3 (9 %) 0.73 (0.19–2.91)
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is well established that mortality of patients with acute 
respiratory distress syndrome (ARDS) is lower using low 
tidal volumes approximating 6 ml/kg of predicted body 
weight [38]. Even in patients without criteria for ARDS, 
the use of low tidal volumes may reduce the risk of devel-
oping ARDS [39]. In our study, the majority of patients 
treated with NIV had clinical criteria for ARDS accord-
ing to the recent definition [40], and the expiratory tidal 
volumes delivered to these patients under NIV were 
around 9.0  ml/kg of predicted body weight. Although 
such high volumes are similar to those reported in 
recent studies focusing on NIV in acute respiratory fail-
ure [20, 34], they could be particularly deleterious by 
worsening lung injury. Indeed, in the study by Carteaux 
and colleagues, an expired tidal volume above 9.5 ml/kg 
of predicted body weight was a strong predictor of NIV 
failure in hypoxemic patients [36]. Despite the absence 
of expired tidal volume assessment in the HFNC group, 
the higher intubation rate observed in the NIV group 
may be explained by the high proportion of patients with 
an expired tidal volume above 9.5  ml/kg of predicted 
body weight (46 % of the patients treated with NIV). In 
addition, any potential deleterious effect of delayed intu-
bation in patients treated with NIV [41, 42] can be ruled 
out as time from ICU admission to intubation was not 
longer than in patients treated with HFNC alone.
Limitations
Our study has several limitations. First, the study was 
monocentric and performed in a unit with experience 
in noninvasive management of immunocompromised 
patients with acute respiratory failure. Indeed, each 
year about 15 immunocompromised patients are 
treated with first-line noninvasive ventilatory support, 
which is close to the number of patients admitted in 
other highly skilled centers [2, 26]. Therefore, these 
results could not be extrapolated to centers with less 
experience. Second, the retrospective nature of the 
study might have induced selection bias despite the 
careful classification of patients included in the anal-
ysis. Indeed, the baseline characteristics of patients 
were not similar as patients in the HFNC group were 
older and as there was a higher proportion of patients 
with respiratory acidosis in the NIV group. NIV could 
have been preferentially used in hypercapnic patients 
due to its efficacy in correction of alveolar hypoven-
tilation [43]. Therefore, the most severe patients 
might have been more frequently treated with NIV 
than with HFNC alone. Nevertheless, functional sta-
tus before ICU admission and baseline severity scores 
were similar between the two groups. Our intubation 
and mortality rates in the NIV group were similar to 
those reported in the literature [2, 6, 26, 27], thereby 
reinforcing the external validity of our results. Third, 
it is possible that outcomes of immunocompromised 
patients admitted to our ICU over this 8-year period 
had improved in the recent years [44]. However, even 
after forcing the year of ICU admission in the logis-
tic regression model, NIV remained associated with 
intubation and mortality. Obviously, these results do 
Table 3 Multivariate analysis of variables associated with outcomes in the overall population
a Non-collinear variables included in the logistical regression model were Simplified Acute Physiology Score II, Noninvasive ventilation as a first-line therapy, use of 
vasopressors within 24 h after ICU admission, SpO2 at ICU admission, cause of respiratory failure and PaCO2 as a continuous variable. The year of ICU admission was 
forced in the model
b Non-collinear variables included in the logistical regression model were age, PaO2-to-FiO2 ratio at ICU admission, use of noninvasive ventilation as a first-line 
therapy, type of immunosuppression, use of vasopressors in the 24 h after ICU admission, cause of respiratory failure and PaCO2 > 45 mmHg. The year of ICU 
admission was forced in the model
Adjusted odds  
ratio (95 % CI)
p value
Variables independently associated with intubationa
Simplified Acute Physiology Score II, per point 1.04 (1.00–1.08) 0.04
Noninvasive ventilation as a first‑line therapy 3.25 (1.39–7.60) 0.007
Use of vasopressors within 24 h after ICU admission 4.12 (1.32–12.84) 0.02
Variables independently associated with mortality at day 28b
Age (per year) 1.03 (1.00–1.07) 0.04
Use of vasopressors within 24 h after ICU admission 2.83 (1.02–7.91) 0.047
Noninvasive ventilation as a first‑line therapy 3.70 (1.49–9.19) 0.005
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Table 4 Comparison of  baseline characteristics and  outcomes between  propensity score-matched patients treated 
by noninvasive positive pressure ventilation (NIV) or high-flow nasal cannula (HFNC) oxygen therapy alone
NIV (n = 24) HFNC (n = 33) p value
Age (years) 62 ± 11 62 ± 11 0.72
Gender (male) 18 (75 %) 17 (52 %) 0.13
Knaus chronic health status score 0.53
 A 8 (33 %) 9 (27 %)
 B 6 (25 %) 11 (33 %)
 C 10 (42 %) 11 (33 %)
 D 0 (0.0 %) 2 (6.1 %)
Mac Cabe classification 0.27
 1 11 (46 %) 12 (36 %)
 2 6 (25 %) 15 (45 %)
 3 7 (29 %) 6 (18 %)
SAPS II at ICU admission (points) 40 ± 11 44 ± 12 0.52
Modified SOFA score at inclusion (points) 1.5 (0.0–4.0) 3.0 (1.0–6.0) 0.44
Type of immunosuppression 0.19
 Hematologic cancer or neutropenia 12 (50 %) 18 (55 %)
 Solid cancer 7 (29 %) 3 (9.1 %)
 Drug‑induced immunosuppression 5 (21 %) 11 (33 %)
 Acquired immune deficiency syndrome 0 (0.0 %) 1 (3.0 %)
Cause of respiratory failure 0.08
 Documented infection 9 (38 %) 19 (58 %)
 Cardiogenic pulmonary edema 4 (27 %) 3 (9.1 %)
 Specific 6 (25 %) 1 (3.0 %)
 Other identified causes 2 (8.3 %) 6 (18 %)
 Not identified cause 3 (13 %) 4 (12 %)
Clinical and biological parameters at inclusion
 Heart rate (beats/min) 107 ± 21 112 ± 21 0.55
 Systolic blood pressure (mmHg) 140 ± 22 127 ± 23 0.17
 Respiratory rate (breaths/min) 30 ± 6 29 ± 6 0.76
 SpO2 (%) 94 ± 5 96 ± 4 0.10
 Body temperature (°C) 37.9 ± 1.1 37.9 ± 1.1 0.66
 Bilateral lung infiltrates on chest X‑ray 19 (79 %) 31 (93 %) 0.12
 Arterial pH 7.45 ± 0.07 7.46 ± 0.06 0.43
 PaO2‑to‑FiO2 ratio (mmHg) 154 ± 57 156 ± 57 0.98
 PaO2‑to‑FiO2 ratio ≤ 200 mmHg 18 (75 %) 24 (73 %) 0.85
 PaCO2 (mmHg) 39 ± 8 33 ± 5 0.03
 PaCO2 > 45 mmHg 4 (17 %) 1 (3.0 %) 0.15
 Sodium bicarbonate (mmol/l) 26 ± 4 24 ± 4 0.10
Vasopressors within 24 h after ICU admission 1 (4.2 %) 4 (12 %) 0.39
Time from admission to ventilatory support initiation (h) 1 (0–1) 1 (0–1) 0.98
Need for immunosuppressive drug during ICU stay 5 (21 %) 4 (12 %) 0.47
Admission before 2011 12 (50 %) 7 (21 %) 0.04
Primary outcome
 28‑day mortality 10 (42 %) 5 (15 %) 0.03
Secondary outcomes
 Intubation 13 (54 %) 10 (30 %) 0.07
 Mortality of intubated 10/13 (77 %) 4/10 (40 %) 0.07
 Time from admission to intubation (h) 48 (20–78) 35 (22–59) >0.99
 Length of invasive mechanical ventilation (days) 8 (5–18) 5 (3–10) >0.99
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not allow for definitive conclusion on the deleterious 
effects of NIV in this population, and our findings 
need to be confirmed in a randomized trial.
Conclusion
Based on this retrospective cohort study, the use of high-
flow oxygen therapy through nasal cannula alone may be 
associated with better outcomes than noninvasive ven-
tilation in immunocompromised patients admitted to 
intensive care unit for acute respiratory failure.
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